MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

Trial StartPositive

AI Analysis

Summary

Meso Pharmaceuticals completed patient treatment in a chronic back pain study. The stock rose following the announcement, though limited details are provided regarding trial phase, efficacy endpoints, or patient count.

Clinical Trial Data

Outcome Details

Patient treatment completed in chronic back pain study

Importance:4/10

Sentiment:

0.60

clinical trialchronic back painpatient enrollmentstudy completion

Related Companies

$MESO

Read the original article

Published by yahoo_finance on August 18, 2026 3:46 PM

Read Original